Yina Gao1, Jingshu Geng2, Xuan Hong1, Jiping Qi3, Yang Teng1, Yang Yang1, Di Qu4, Gongyan Chen1. 1. Department of Pulmonary Medicine, The Third Affiliated Hospital of Harbin Medical University 150 Hapin Avenue, Nangang, Harbin, China. 2. Department of Pathology, The Third Affiliated Hospital of Harbin Medical University 150 Hapin Avenue, Nangang, Harbin, China. 3. Department of Pathology, The First Affiliated Hospital of Harbin Medincal University Harbin, China. 4. Department of Pulmonary Medicine, The Second Affiliated Hospital of Harbin Medical University 150 Hapin Avenue, Nangang, Harbin, China.
Abstract
PURPOSE: To investigate the correlation among p300, CBP and MLL expression and the clinicopathological characteristics in resected SCLC patients. METHODS: Two hundred and twenty-two resected SCLC patients were included in this study. We evaluated p300, CBP and MLL expression by immunohistochemistry. RESULTS: Patients with high p300 expression had shorter OS and DFS than those with low p300 expression (p = 0.01; p = 0.009, respectively). The patients with CBP-positive tumors had significantly lower OS and DFS than those with CBP-negative tumors (p = 0.005 and p = 0.007, respectively). Moreover, the p300- and CBP-positive (+) group had a significantly poor OS and DFS. The multivariate Cox regression analysis showed that high p300 and CBP expression are independent markers of poor overall survival (p = 0.006; p = 0.017, respectively) in operable SCLC patients. CONCLUSIONS: High p300 and CBP expression are independent prognostic markers of poor overall survival for resected SCLC patients. The combination of p300 and CBP expression may be useful in identifying patients with increased risks of cancer recurrence of SCLC.
PURPOSE: To investigate the correlation among p300, CBP and MLL expression and the clinicopathological characteristics in resected SCLCpatients. METHODS: Two hundred and twenty-two resected SCLCpatients were included in this study. We evaluated p300, CBP and MLL expression by immunohistochemistry. RESULTS:Patients with high p300 expression had shorter OS and DFS than those with low p300 expression (p = 0.01; p = 0.009, respectively). The patients with CBP-positive tumors had significantly lower OS and DFS than those with CBP-negative tumors (p = 0.005 and p = 0.007, respectively). Moreover, the p300- and CBP-positive (+) group had a significantly poor OS and DFS. The multivariate Cox regression analysis showed that high p300 and CBP expression are independent markers of poor overall survival (p = 0.006; p = 0.017, respectively) in operable SCLCpatients. CONCLUSIONS: High p300 and CBP expression are independent prognostic markers of poor overall survival for resected SCLCpatients. The combination of p300 and CBP expression may be useful in identifying patients with increased risks of cancer recurrence of SCLC.
Authors: A Tomita; M Towatari; S Tsuzuki; F Hayakawa; H Kosugi; K Tamai; T Miyazaki; T Kinoshita; H Saito Journal: Oncogene Date: 2000-01-20 Impact factor: 9.867
Authors: Martin Peifer; Lynnette Fernández-Cuesta; Martin L Sos; Julie George; Danila Seidel; Lawryn H Kasper; Dennis Plenker; Frauke Leenders; Ruping Sun; Thomas Zander; Roopika Menon; Mirjam Koker; Ilona Dahmen; Christian Müller; Vincenzo Di Cerbo; Hans-Ulrich Schildhaus; Janine Altmüller; Ingelore Baessmann; Christian Becker; Bram de Wilde; Jo Vandesompele; Diana Böhm; Sascha Ansén; Franziska Gabler; Ines Wilkening; Stefanie Heynck; Johannes M Heuckmann; Xin Lu; Scott L Carter; Kristian Cibulskis; Shantanu Banerji; Gad Getz; Kwon-Sik Park; Daniel Rauh; Christian Grütter; Matthias Fischer; Laura Pasqualucci; Gavin Wright; Zoe Wainer; Prudence Russell; Iver Petersen; Yuan Chen; Erich Stoelben; Corinna Ludwig; Philipp Schnabel; Hans Hoffmann; Thomas Muley; Michael Brockmann; Walburga Engel-Riedel; Lucia A Muscarella; Vito M Fazio; Harry Groen; Wim Timens; Hannie Sietsma; Erik Thunnissen; Egbert Smit; Daniëlle A M Heideman; Peter J F Snijders; Federico Cappuzzo; Claudia Ligorio; Stefania Damiani; John Field; Steinar Solberg; Odd Terje Brustugun; Marius Lund-Iversen; Jörg Sänger; Joachim H Clement; Alex Soltermann; Holger Moch; Walter Weder; Benjamin Solomon; Jean-Charles Soria; Pierre Validire; Benjamin Besse; Elisabeth Brambilla; Christian Brambilla; Sylvie Lantuejoul; Philippe Lorimier; Peter M Schneider; Michael Hallek; William Pao; Matthew Meyerson; Julien Sage; Jay Shendure; Robert Schneider; Reinhard Büttner; Jürgen Wolf; Peter Nürnberg; Sven Perner; Lukas C Heukamp; Paul K Brindle; Stefan Haas; Roman K Thomas Journal: Nat Genet Date: 2012-09-02 Impact factor: 38.330
Authors: Zibo Zhao; Aileen P Szczepanski; Natsumi Tsuboyama; Hiam Abdala-Valencia; Young Ah Goo; Benjamin D Singer; Elizabeth T Bartom; Feng Yue; Lu Wang Journal: Cancer Res Date: 2021-08-02 Impact factor: 12.701